TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer

BACKGROUND: FOLFOXIRI plus bevacizumab is considered a standard option in the upfront treatment of clinically selected patients with metastatic colorectal cancer irrespective of RAS and BRAF molecular status. The randomised MACBETH and VOLFI studies showed that a modified FOLFOXIRI regimen in combin...

Descripción completa

Detalles Bibliográficos
Autores principales: Borelli, Beatrice, Moretto, Roberto, Lonardi, Sara, Bonetti, Andrea, Antoniotti, Carlotta, Pietrantonio, Filippo, Masi, Gianluca, Burgio, Valentina, Marmorino, Federica, Salvatore, Lisa, Rossini, Daniele, Zaniboni, Alberto, Zucchelli, Gemma, Martignetti, Angelo, Di Battista, Monica, Pella, Nicoletta, Passardi, Alessandro, Boccaccino, Alessandra, Leone, Francesco, Colombo, Camilla, Granetto, Cristina, Vannini, Francesca, Marsico, Valentina Angela, Martinelli, Erika, Antonuzzo, Lorenzo, Vitello, Stefano, Delliponti, Laura, Boni, Luca, Cremolini, Chiara, Falcone, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6045747/
https://www.ncbi.nlm.nih.gov/pubmed/30018814
http://dx.doi.org/10.1136/esmoopen-2018-000403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6045747/
https://www.ncbi.nlm.nih.gov/pubmed/30018814
http://dx.doi.org/10.1136/esmoopen-2018-000403

Ejemplares similares